Cancer Research and Treatment

Randomized, Multi-center Phase II Trial of Docetaxel Plus Cisplatin Versus Etoposide Plus Cisplatin as the First-line Therapy for Patients with Advanced Non-Small Cell Lung Cancer: Nam-Su Lee, Hee-Sook Park, Jong-Ho Won, Dae-Sik Hong, Su-Taek Uh, Sang-Jae Lee, Joo-Hang Kim, Se-Kyu Kim, Myung-Ju Ahn, Jung-Hye Choi, Suk-Chul Yang, Jung-Ae Lee, Keun-Seok Lee, Chang-Yeol Yim, Yong-Chul Lee, Chul-Soo Kim, Moon-Hee Lee, Kab-Do Jung, Hanlim Moon, Yl-Sub Lee; Cancer Res Treat. 2005;37(6):332-338. Published online December 31, 2005; DOI: https://doi.org/10.4143/crt.2005.37.6.332

Purpose

We prospectively conducted a multi-center, open-label, randomized phase II trial to compare the efficacy and safety of docetaxel plus cisplatin (DC) and etoposide plus cisplatin (EC) for treating advanced stage non-small cell lung cancer (NSCLC).

Materials and Methods

Seventy-eight previously untreated patients with locally advanced, recurrent or metastatic NSCLC were enrolled in this study. The patients received cisplatin 75 mg/m² on day 1 and either docetaxel 75 mg/m² on day 1 or etoposide 100 mg/m² on days 1 to 3 in the DC or EC arm, respectively, every 3 weeks.

Results

The objective response rate was 39.4% (15/38) and 18.4% (7/38) (p=0.023) in the DC and EC arms, respectively. The median time to progression (TTP) was 5.9 and 2.7 months (p=0.119), and the overall survival was 12.1 and 8.7 months (p=0.168) in the DC and EC arms, respectively. The prognostic factors for longer survival were an earlier disease stage (stage III, p=0.0095), the responders to DC (p=0.0174) and the adenocarcinoma histology (p=0.0454). The grades 3 and 4 toxicities were similar in both arms, with more febrile neutropenia (7.9% vs. 0%) and fatigue (7.9% vs. 0%) being noted in the DC arm.

Conclusion

DC offered a superior overall response rate than does EC, along with tolerable toxicity profiles, although the DC drug combination did not show significantly improved survival and TTP.

Citations

Citations to this article as recorded by

Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis
Sarah Goring, Nebibe Varol, Nathalie Waser, Evan Popoff, Greta Lozano-Ortega, Adam Lee, Yong Yuan, Laura Eccles, Phuong Tran, John R. Penrod
Lung Cancer.2022; 170: 122. CrossRef

10,030 View
67 Download
1 Crossref

Comparison of Tropisetron with Ondansetron in the Prevention of Cisplatin-induced Nausea and Vomiting: Kyung Shick Lee, Ji Youn Han, Hanlim Moon, Bok Kun Lee, Seok Goo Cho, Jong Youl Jin, Young Sun Hong, Hoon Kyo Kim; J Korean Cancer Assoc. 1997;29(2):332-339.

Abstract PDF: PURPOSE
Tropisetron (Nabovan (R)) is a new specific 5-HT3 receptor antagonist with a long terminal half life in plasma and high bioavailability after oral intake. We compared the antiemetic effectiveness and tolerability of tropisetron with ondansetron in the highly emetogenic chemotherapy (including cisplatin > or =50 mg/m2).
MATERIALS AND METHODS
Thirty-nine patients were administered in a randomized, multicenter, open, cross-over study and received either tropisetron plus dexamethasone (n=31) or ondansetron plus dexamethasone (n=34) during six days of two successive cycles of chemotherapy.
RESULTS
Total control of vomiting with either Ondansetron or tropisetron was 94.2 % vs 93.5 % in D1 (P=0.157); 90.6 % vs 93.1 % in D2 (P=0.18); 90.3 % vs 93.1 % in D3 (P=0.655); 96.4% vs 96.4 % in D4 (P=0.157); 96.4 % vs 100 % in D5 (P=0.317); 96.4 % vs 100% in D6, respectively. The duration of nausea showed significant decreasements in tropisetron at D5 and D6 (P=0.025, P=0.03, respectively), but the severity of nausea and performance status showed no significance. Headache and constipation were the most common side effects in both groups.
CONCLUSION
There was no significant difference in efficacy and tolerability between tropisetron and ondansetron in the cisplatin-based chemotherapy.

4,013 View
32 Download

Etoposide, adriamycin and cisplatin(EAP) chemotherapy in advanced gastric cancer: Jong Youl Jin, Kwang Moo Yoon, Hanlim Moon, Young Seon Hong, Hoon Kyo Kim, Kyung Shik Lee, Boo Sung Kim, Dong Jip Kim, Cho Hyun Park, In Chul Kim, Hyun Kwon Ha; J Korean Cancer Assoc. 1991;23(2):273-278.

Abstract PDF: No abstract available.

3,251 View
19 Download

The Results of Radiation Therapy for Metastatic Spinal Cord Compression: Ji Youn Han, Jae You Kim, Hong Suk Chang, Byung Ok Choi, Byung Gil Choi, Hanlim Moon, Young Sun Hong, Sei Chul Yoon, Hoon Kyo Kim, Kyung Shick Lee, Dong Jip Kim; J Korean Cancer Assoc. 1996;28(1):138-145.

Abstract PDF: Spinal cord compression is a common neurologic complication of advanced cancer, and it is a medical emergency because delay in treatment often results in irreversible paralysis. The treatment-goal of metastatic spinal cord compression is the preservation or restoration of neurologic function. We retrospectively analyzed the results of radiation therapy for metastatic spinal cord compression from January 1987 to May 1992 to assess the neuro1ogic recovery rate of metastatic spinal cord compression by radiation therapy. The results were as follows: ¨cThe most common cause of metastatic spinal cord compression was lung cancer (24%), followed by hepatoma (18%), gastric cancer (8%). ¨e Eighty seven percent of patients presented with localized back pain which preceded diagnosis of spinal cord compression by several weeks. ¨e At diaanosis, 71 % of patients were presented in paralytic status. 27 % of the patients who were ambulatory and 15 % of the paralytic patients before treatment were remained ambulatory or became ambulatory after radiation therapy. ¨eThe duration of survival of all patients were 6 to 159 days (median 55 days). It seemed that the poor outcome of radiation therapy was related to the aggressive biologic features and radioresistance of the primary tumors rather than the neurologic status before the treatment. The prospective study with other treatment modalities such as anterior resection with or without radiation therapy is necessary for improving the neurologic recovery rate.

2,983 View
17 Download

Search